Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Neuropeptides: important … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Neuropeptides: important regulators of joint homeostasis

Artikel i vetenskaplig tidskrift
Författare Birgitta Gatenholm
Mats Brittberg
Publicerad i Knee Surgery, Sports Traumatology, Arthroscopy
Volym 27
Nummer/häfte 3
Sidor 942-949
ISSN 09422056
Publiceringsår 2019
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för ortopedi
Sidor 942-949
Språk en
Ämnesord Inflammation, Joint pain, Neuropeptides, Osteoarthritis
Ämneskategorier Ortopedi

Sammanfattning

© 2018, European Society of Sports Traumatology, Knee Surgery, Arthroscopy (ESSKA). Purpose: This review explores the mechanisms of joint pain with a special focus on the role of neuropeptides in pain transmission and their potential role in the progression of joint degeneration as seen in osteoarthritis. Methods: A literature search was performed on papers published between January 1990 and September 2017 using the Web of Science Core Collection, MEDLINE and Scopus databases. Results: What is seen in the subchondral bone and synovia is mirrored in the central nervous system (CNS). Substance P, calcitonin gene-related peptide, vasoactive intestinal peptide and neuropeptide Y are the major peptides involved both in the generation of pain as well as reducing pain post-joint trauma. The interplay between them and other neuropeptides and cytokines influence how noxious stimuli are transduced, transmitted and modulated for a final pain perception as part of a complex cascade of events. There is a close interaction between the different components in the joint that together cross-talk to adapt to load and catabolic factors during injury and inflammation. Conclusion: The articular joint should be seen as an organ where local joint pain development and maintenance is influenced by interplay between the local transmitters in the joints as well as their dependence on the CNS. A slow-release cocktail of mixed antibodies targeted against neuropeptides and receptor blockers/stimulators involved in the events of early joint pain or any inflammatory joint disease is a future treatment target. Level of evidence: V.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?